This study is testing a new immunotherapy called DOC1021 for adults recently diagnosed with glioblastoma (a type of brain cancer). Researchers want to see if adding DOC1021 and pIFN (another treatment) to standard care improves how long patients live, and if it is safe. DOC1021 is a "dendritic cell vaccine" that uses your own immune cells to fight the cancer. You might be able to join if you are 18 or older, have newly diagnosed glioblastoma (specifically, IDH-wt type), and are a candidate for surgery. The study aims to enroll 180 participants. The main goal is to measure overall survival (how long patients live) over 5 years.

Study design

This interventional study plans to enroll 180 participants. It compares DOC1021 plus standard care to standard care alone.

What's involved

If you are in the DOC1021 group, you will have a blood collection (leukapheresis), receive three DOC1021 injections every two weeks, and six weekly pIFN injections. All participants will have regular clinic visits to check quality of life and symptoms.

Compensation

Not stated in the trial record.

Follow-up

Participants' overall survival will be measured for up to 5 years after they join the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.